Reshaping Dyslipidaemia Treatment with Bempedoic Acid—A Narrative Review
Dyslipidaemia is one of the main causes of atherosclerotic cardiovascular disease (ASCVD) worldwide. Although statins remain the cornerstone of lipid-lowering therapy, many patients do not achieve optimal target levels of low-density lipoprotein cholesterol (LDL-C) due to intolerance or inadequate r...
Saved in:
Main Authors: | Dominik Strikic, Zvonimir Begic, Ivana Radman, Fran Zlopasa, Jana Mateljic, Ivica Zec, Marina Titlic, Ana Marija Sliskovic, Ivan Pecin, Zeljko Reiner, Iveta Mercep |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2025-06-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/13/6/1460 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bempedoic Acid: Safety and Efficiacy of a New Lipid-Lowering Agent
by: I. A. Mazerkina, et al.
Published: (2023-09-01) -
Triple Non-Statin Therapy with Ezetimibe, Inclisiran, and Bempedoic Acid in Patients with Genetically Confirmed Statin-Induced Rhabdomyolysis: A Dual Case Report
by: Jozef Dodulík, et al.
Published: (2025-05-01) -
The Pathogenetic Basis of the Action of Bempedoic Acid
by: A. S. Petrosyan, et al.
Published: (2023-01-01) -
South African Dyslipidaemia Guideline Consensus Statement
by: E.Q. Klug, et al.
Published: (2015-03-01) -
Acetate alleviates glucose dysregulation and atherogenic dyslipidaemia in experimentally induced PCOS
by: STEPHANIE ESOSA JOY ARELOEGBE, et al.
Published: (2025-06-01)